ANDA 215266, held by Padagis Israel. Halobetasol Propionate.
As of Nov 15, 2026, ANDA 215266 (Halobetasol Propionate), held by Padagis Israel, was first approved by FDA on Aug 11, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2023 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Halobetasol Propionate0.05% ยท aerosol, foam;topical | Halobetasol Propionate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
